The role played by serine proteases in the development and worsening of vascular complications in type 1 diabetes mellitus

Current Diabetes Reviews

Volumn 2, Issue 3, 2006, Pages 295-305

  Finotti, Paola ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Diabetes mellitus; Heat shock proteins; Immune complexes; Immunoglobulins; Insulin dependent; Serine proteases

Indexed keywords

PROTEINASE INHIBITOR; SERINE PROTEINASE;

BLOOD CLOTTING; DIABETIC ANGIOPATHY; DIABETOGENESIS; DISEASE EXACERBATION; DISEASE MARKER; DRUG RESEARCH; ENZYME ACTIVITY; ENZYME DEFECT; ENZYME STRUCTURE; FIBRINOLYSIS; HUMAN; IMMUNITY; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW;

ANTIBODY FORMATION; CELL DIVISION; DIABETES MELLITUS, TYPE 1; DIABETIC ANGIOPATHIES; HEAT-SHOCK PROTEINS; HUMANS; IMMUNITY, CELLULAR; IMMUNOGLOBULINS; INFLAMMATION; MODELS, BIOLOGICAL; MUSCLE, SMOOTH, VASCULAR; SERINE ENDOPEPTIDASES;

EID: 33746894222     PISSN: 15733998     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339906777950624     Document Type: Review

References (143)

1. Schechter I and Berger A. On the size of the active site in proteases. Biochem Biophys Res Common 1967; 27: 157-62.
2. Yousef GM, Eliott MB, Kopolovic AD, Serry E and Diamandis EP. Sequence and evolutionary analysis of the human trypsin subfamily of serine peptidases. Biochim Biophys Acta 2004; 1698: 77-86.
3. Tanaka K, Nakamura T and Ichihara A. A unique trypsin-like protease associated with plasma membranes of rat liver. J Biol Chem 1986; 261: 2610-5.
4. Lemberg MK, Martoglio B. On the mechanism of SPP-catalysed intramembrane proteolysis; conformational control of peptide bond hydrolysis in the plane of the membrane. FEBS Lett 2004; 564: 213-8.
5. Powers JC and Harper JW. In: Barrett AJ and Salvesen G Eds, Proteinase Inhibitors Amsterdam, Elsevier, 1986; 55-152.
6. Werb Z. ECM and cell surface proteolysis: regulating cellular ecology. Cell 1997; 91: 439-42.
7. Krem MM, Rose T and Di Cera E. The C-terminal sequence encodes function in serine proteases. J Biol Chem 1999; 274: 28063-6.
8. Hancock MA, Spencer CA and Koschinsky ML. Definition of the structural elements in plasminogen required for high-affinity binding to apolipoprotein(a): a study utilizing surface plasmon resonance. Biochemistry 204; 43: 12237-48.
9. Shuster AM, Gololobov GV, Kvashuk OA, Bogomolova AE, Smirnov IV, Gabibov AG. DNA hydrolyzing autoantibodies. Science 1992; 296: 665-7.
10. Li L, Kalaga R, Paul S. Proteolytic components of serum IgG preparations. Clin Exp Immunol 2000; 120;. 261-6.
11. Sun M, Gao QS, Li L and Paul S. Proteolytic activity of an antibody light chain. J Immunol 1994; 153: 5121-.
12. Erhan S, Greller LD. Do immunoglobulins have proteolytic activity? Nature 1974; 51: 353-5.
13. Paul S, Volle DJ, Beach CM, Johnson DR, Powell MJ, Massey RJ. Catalytic hydrolysis of vasoactive intestinal peptide by human autoantibody. Science 1989; 244: 1158-62.
14. Gao Q-S, Sun M, Rees AR and Paul S. Site-directed mutagenesis of proteolytic antibody light chain. J Mol Biol 1995; 253: 658-64.
15. McLean JW, Tomlinson JE, Kuang W-J et al. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 1987; 330: 132-7.
16. Feldman DE and Frydman J. Protein folding in vivo: the importance of molecular chaperones. Curr Opin Struct Biol 2000; 10: 26-33.
17. Lee AS. The glucose-regulated proteins: stress induction and clinical applications. Trends Biochem Sci 2001; 26: 504-10.
18. Binder RI, Blachere NE, Srivastava PK. Heat shock protein-chaperoned peptides but not free peptides introduced into the cytosol are presented efficiently by major histocompatibility complex I molecules. J Biol Chem 2001; 276: 17163-71.
19. Li Z, Menoret A, Srivastava PK. Role of heat shock proteins in antigen presentation and cross-presentation. Curr Opin Immunol. 2002; 14: 45-51.
20. Menoret A, Li ZL, Niswongers ML, Altmeyer A, Srivastava PK. An endoplasmic reticulum protein implicated in chaperoning peptides to major histocompatibility of class I is an aminopeptidase. J Biol Chem 2001; 276: 33313-8.
21. Faccio L, Fusco C, Chen A, Martinotti S, Bonventre JV and Zervos AS. Characterization of a novel human serine protease that has extensive homology to bacterial endoprotease HtrA and is regulated by kidney ischemia. J Biol Chem 2000; 275: 2581-8.
22. Hu SI, Carozza M, Klein M, Nantermet P, Luk D, Crow RM. Human HtrA, an evolutionarily conserved serine protease identified as a differentially expressed gene product in osteoarthritic cartilage. J Biol Chem 1998; 273: 3406-12.
23. Spiess C, Beil A, Ehrmann M. A temperature dependent switch from chaperone to protease in a widely conserved heat shock protein. Cell 1999; 97: 339-47.
24. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nature Med 2000; 6: 389-95.
25. Michael JP, Sotiropoulou G, Pampalakis G, et al. Biochemical and enzymatic characterization of human kallikrein 5 (hK5), a novel serine protease potentially involved in cancer progression. J Biol Chem 2005; 280: 14628-35.
26. Yousef GM, Magklara A, Diamandis EP. KLK12 is a novel serine protease and a new member of the human kallikrein gene family - Differential expression in breast cancer. Genomics 2000; 69: 331-41.
27. Prager GW, Breuss JM, Steurer S, Mihaly J and Binder DR. Vascular endothelial growth factor (VEGF) induces rapid prourokinase (pro-uPA) activation on the surface of endothelial cells. Blood 2004; 103: 955-62.
28. Gonzales-Gronow M, Grenett HE, Weber MR, Gawdi G and Pizzo SV. Interaction of plasminogen with dipeptidyl peptidase IV initiates a signal transduction mechanism which regulates expression of matrix metalloproteinase-9 by prostate cancer cells. Biochem J 2001; 355: 39-40.
29. Tani K, Ogushi F, Schimizu T, Sone S. Protease-induced leukocyte chemotaxis and activation: roles in host defense and inflammation. J Med Invest 2001; 48: 133-41.
30. Nie J, Pei D. Rapid inactivation of alpha-1-proteinase inhibitor by neutrophil specific leukolysin/membrane-type matrix metalloproteinase 6. Exp Cell Res 2004, 296: 145-50.
31. Olofsson B, Korpelainen E, Pepper MS, et al. Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Proc Natl Acad Sci USA 1998; 95: 11709-14.
32. Niemann MA, Baggott JE, Miller EJ. Binding of SPAAT, the 44-residue C-terminal peptide of alpha 1-antitrypsin to proteins of the extracellular matrix. J Cell Biochem 1997, 66: 346-57.
33. Zelvyte I, Lindgren S, Janciauskiene S. Multiple effects of alphal-antitrypsin on breast carcinoma MDA-MB 468 cell growth and invasiveness. Eur J Cancer Prev 2003; 12: 117-24.
34. phox-containing NADPH oxidase. Circ Res 2001; 89: 47-54.
35. Dupuy E, Habib A, Lebret M, Yang R, Levy-Toledano S and Tobelem G. Thrombin induces angiogenesis and vascular endothelial growth factor expression in human endothelial cells: possible relevance to HIF-1α. J Thromb Haemost 2003; 1: 1096-102.
36. Coughlin SR. How the protease thrombin talks to cells. Proc Natl Acad Sci USA 1999; 96: 11023-27.
37. Archiniegas E., Neves CY, Candelle D, Cardier JE. Thrombin and its protease-activated receptor-1 (PAR1) participate in the endothelial-mesenchimal transdifferentiation process. DNA Cell Biol 2004; 23: 815-25.
38. Yu J, Bian D, Mahanivong C, Cheng RK, Zhou W and Huang S. p38 mitogen-activated protein kinase regulation of endothelial cell migration depends on urokinase plasminogen activator expression. J Biol Chem 2004; 279: 50446-54.
39. Camerer E, Kataoka H, Kahn M, Lease K and Coughlin SR. Genetic evidence that protease-activated receptors mediate factor Xa signaling in endothelial cells. J Biol Chem 2002; 277: 16081-7.
40. Darmoul D, Gratio V, Devaud H and Laburthe M. Protease-activated receptor 2 in colon cancer. J Biol Chem 2004; 279: 20927-34.
41. Morale M, De Negri E, Carmassi F. Fibrin(ogen) and diabetes mellitus: don't forget fibrinolisis. Diabetologia, 1997; 40:735-7.
42. Riewald M, Petrovan RJ, Donner A, Mueller BM, Ruf W. Activation of endothelial cell protease activated receptor 1 by the Protein C pathway. Science 2002; 296: 1880-2.
43. Andersen H, Greenberg DL, Fujikawa K, Xu W, Chung DW and Davie EW. Protease-activated receptor 1 is the primary mediator of thrombin-stimulated platelet procoagulant activity. Proc Natl Acad Sci USA 1999; 96: 11189-93.
44. Thorgensen AM, Janason JH, Boman K, et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation 1998; 98: 2241-7.
45. Plow EF and Hoover-Plow J. The functions of plasminogen in cardiovascular disease. Trends Cardiovasc Med 2004: 14: 180-6.
46. Jenkins GR, Seiffert D, Parmer RJ and Miles LA. Regulation of plasminogen gene expression by interleukin-6. Blood 1997; 89: 2394-403.
47. Wallin RPA, Lundqvist A, Morè SH, von Bonin A, Kiessling R and Ljunggren H-G. Heat-shock proteins as activators of the innate immune system. Trends Immunol 2002; 23: 130-5.
48. Ishizawa K, Kubo H, Yamada M, et al. Hepatocyte growth factor induces angiogenesis in injured lungs through mobilizing endothelial progenitor cells. Biochem Biophys Res Commun 2004; 324: 276-80.
49. Van Belle E, Witzenbichler B, Cchen D, et al. Potentiated angiogenic effect of scatter factor/hepatocyte growth factor via induction of vascular endothelial growth factor: the case of paracrine amplification of angiogenesis. Circulation 1998; 97: 381-90.
50. O'Neil CH, Boffa MB, Hancock MA, Pickering JG and Koschinsky ML. Stimulation of vascular smooth muscle cell proliferation and migration by apolipoprotein(a) is dependent on inhibition of transforming growth factor-β activation and on the presence of kringle IV type 9. J Biol Chem 2004; 279: 55187-95.
51. Pandiella A, Bosenberg M, Huang EJ, Besmer P and Massagué J. Cleavage of membrane-anchored growth factors involves distinct protease activities regulated through common mechanisms. J Biol Chem 1992; 267: 24028-33.
52. Birò A, Hérincs Z, Fellinger E, et al. Characterization of a trypsin-like serine protease of activated B cells mediating the cleavage of surface proteins. Biochem Biophys Acta 2003; 1624: 60-9.
53. Cardell S, Möller G. Trypsin does not reconstitute responsiveness to lipopolysaccharide in the strain C3H6Hej, but is a B cell mitogen-like lipopolysaccharide, stimulating a different subpopulation. Scand J Immunol 1989; 29: 143-9.
54. Reinhold D, Kahne T, Steinbrecher A, et al. The role of dipeptidyl peptidase IV (DP IV enzymatic activity in T cell activation and autoimmunity. Biol Chem 2002; 383: 1133-8.
55. Chen C, Darrow AL, Qi JS, D'Andrea MR, Andrade-Gordon P. A novel serine protease predominately expressed in macrophages. Biochem J 2003; 374: 97-107.
56. Birò A, Sarmay G, Rozsnyay Z, Klein E, Gergely J. A trypsin-like serine protease activity on activated human B cells and various B cell lines. Eur J Immunol 1992; 22: 2547-53.
57. Utsonomiya N and Nakanishi M. A serine protease triggers the initial step of transmembrane signalling in cytotoxic T cells. J Biol Chem 1986; 261: 16514-7.
58. Planque S, Bangale Y, Song X-T, et al. Ontogeny of proteolytic immunity. J Biol Chem 2004; 279: 14024-32.
59. Xu Q. Role of heat shock proteins in atherosclerosis. Arterioscler Thromb Vasc Biol 2002; 22: 1547-59.
60. Paris S, Denis H, Delaive E, et al. Up-regulation of 94-kDa glucose-regulated protein by hypoxia-inducible factor-1 in human endothelial cells in response to hypoxia. FEBS Lett 2005; 579: 105-14.
61. Le Boeuf F, Houle F and Huot J. Regulation of vascular endothelial growth factor receptor 2-mediated phosphorylation of focal adhesion kinase by heat shock protein 90 and Src kinase activities. J Biol Chem 2004; 279: 39175-85.
62. Madamanchi NP, Li S, Patterson C and Runge MS. Thrombin regulates vascular smooth muscle cell growth and heat shock proteins via the JAK-STAT pathway. J Biol Chem 2001; 276: 8915-24.
63. Pai KS, Mahajan VB, Lau A and Cunningham DD. Thrombin receptor signaling to cytoskeleton requires Hsp90. J Biol Chem 2001; 276: 32642-7.
64. Fukao H, Hagiya Y, Ueshima S, et al. Effect of heat shock on the expression of urokinase-type plasminogen activator receptor in human umbilical vein endothelial cells. Thromb Haemost 1996; 75: 352-8.
65. Liao D-F, Jin Z-G, Baas AS, et al. Purification of secreted oxidative stress-induced factors from vascular smooth muscle cells. J Biol Chem 2000; 275: 189-96.
66. Polanowska-Grabowska R, Gear AR. Heat-shock proteins and platelet function. Platelets 200; 11: 6-22.
67. Suttitanamongkol S, Gear AR, Polanowska-Grabowska R. Geldanamycin disrupts platelet-membrane structure, leading to membrane permeabilization and inhibition of platelet aggregation. Biochem J 2000; 345: 307-14.
68. Asea A, Rehli M, Kabingu E, et al. Novel signal transduction pathway utilized by extracellular Hsp70. J Biol Chem 2002; 277: 15028-34.
69. Liu B, Dai J, Zheng H, Stoilova D, Sun S and Li Z. Cell surface expression of an endoplasmic reticulum resident heat shock protein gp96 triggers MyD88-dependent systemic autoimmune diseases. Proc Natl Acad Sci USA 2003; 100: 15824-9.
70. Vabulas RM, Braedel S, Hilf N, et al. The endoplasmic reticulum-resident heat shock protein Gp96 activates dendritic cells via the Toll-like receptor 2/4 pathway. J Biol Chem 2002; 277: 20847-53.
71. Xu Q, Schett G, Seitz CS, Hu Y, Gupta RS, Wick G. Surface staining and cytotoxic activity of heat-shock protein 60 antibody in stressed aortic endothelial cells. Circ Res 1994; 75: 1078-85.
72. Habich C, Kempe K, Burkart V, et al. Identification of the heat shock protein 60 epitope involved in receptor binding on macrophages. FEBS Lett 2004; 568: 65-9.
73. Reed RC, Berwin B, Baker JP and Nicchitta CV. GRP94/gp96 elicits ERK activation in murine macrophages. J Biol Chem 2003; 278: 31853-60.
74. Xu Q, Willeit J, Marosi M, et al. Association of serum antibodies to heat-shock protein 65 with carotid atherosclerosis. Lancet 1993; 341: 255-9.
75. Milloning G, Malcom GT, Wick G. Early inflammatory-immunological lesions in juvenile atherosclerosis from the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) study. Atherosclerosis 2002; 160: 441-8.
76. Pelham HR. Speculations on the functions of the major heat shock and glucose-regulated proteins. Cell 1986; 46: 959-61.
77. Pockley AG, Wu R, Lemne C, Kiessling R, de Faire U, Frostegård J. Circulating heat shock protein 60 is associated with early cardiovascular disease. Hypertension 200; 36: 303-7.
78. Mayr M, Metzler B, Kiechl S, et al. Endothelial cytotoxicity mediated by serum antibodies to heat shock proteins of Escherichia coli and Chlamidia pneumoniae. Circulation 1999; 99: 1560-6.
79. Portaro FCV, Hayashi MAF, de Arauz LJ, et al. The Mycobacterium leprae hsp65 displays proteolytic activity. Mutagenesis studies indicate that the M. leprae hsp65 proteolytic activity is catalytically related to the HslVU protease. Biochemistry 2002; 41: 7400-6.
80. Inouye S, Izu H, Takaki E, et al. Impaired IgG production in mice deficient for heat shock transcription factor 1. J Biol Chem 2004; 279: 38701-9.
81. Ferris DK, Harel-Bellan A, Morimoto RI, Welch WJ and Farrar WL. Mitogen and lymphokine stimulation of heat shock proteins in T lymphocytes. Proc Natl Acad Sci USA 1988; 85: 3850-4.
82. Stephanou A, Amin V, Isen berg DA, Akira S, Kishimoto T and Latchman DS. Interleukin 6 activates heat-shock protein 90β gene expression. Biochem J 1997; 321: 103-6.
83. Suematsu S, Matsuda T, Aozasa K, et al. IgG1 plasmacytosis in interleukin 6 transgenic mice. Proc Natl Acad Sci USA 1989; 86: 7547-51.
84. Melnick J, Aviel S and Argon Y. The endoplasmic reticulum stress protein GRP94, in addition to BiP, associates with unassembled immunoglobulin chains. J Biol Chem 1992; 267: 21303-6.
85. Goral J, Shenoy S, Mohanakumar T and Clancy J. Antibodies to 70 kDa and 90 kDa heat shock proteins are associated with graft-versus-host disease in peripheral blood stem cell transplant recipients. Clin Exp Immunol 2002; 127: 553-9.
86. Kim H. Diagnostic significance of antibodies to heat shock proteins. Clin Chim Acta 2003; 337: 1-10.
87. McCrae KR, deMichele A, Samuels P, et al. Detection of endothelial cell-reactive immunoglobulin in patients with anti-phospholipid antibodies. Br J Haematol 1991; 79: 595-605.
88. Kolev K, Gombás J, Vàradi B, et al. Immunoglobulin G from patients with antiphospholipid syndrome impairs the fibrin dissolution with plasmin. Thromb Haemost 2002; 87: 502-8.
89. Yang C-D, Hwang K-K, Yan W, et al. Identification of anti-plasmin antibodies in the antiphospholipid syndrome that inhibit degradation of fibrin. J Immunol 2004; 172: 5765-73.
90. Hwang K-K, Grossman JM, Visvanathan S, et al. Identification of anti-thrombin antibodies in the antiphospholipid syndrome that interfere with the inactivation of thrombin by antithrombin. J Immunol 2001; 167: 7192-8.
91. Oosting JD, Derksen RHWM, Bobbink WG, Hackeng TM, Bouma BN and de Groot PG. Antiphospholipid antibodies directed against a combination of phospholipid with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanism? Blood 1993; 81 2618-25.
92. Cugno M, Dominguez M, Cabibbe M, et al. Antibodies to tissue-type plasminogen activator in plasma from patients with primary antiphospholipid syndrome. Br J Haematol 2000: 108: 871-5.
93. Liu Z, Li N, Diaz LA, Shipley JM, Senior RM and Werb Z. Synergy between a plasminogen cascade and MMP-9 in autoimmune disease. J Clin Invest 2005; 115: 879-87.
94. Takada K, Takiguchi M, Konno A and Inaba M. Autoimmunity against a tissue kallikrein in IQI/Jic mice. J Biol Chem 2005; 280: 3982-8.
95. Mayet W-J and Meyer zum Büschenfelde K-H. Antibodies to proteinase 3 increase adhesion of neutrophils to human endothelial cells. Clin Exp Immunol 1993; 94: 440-6.
96. Uehara A, Sugawara Y, Sasano T, Takada H and Sugawara S. Proinflammatory cytokines induce proteinase 3 as membrane-bound and secretory forms in human oral epithelial cells and antibodies to proteinase 3 activate the cells through protease-activated receptor-2. J Immunol 2004; 173: 4179-89.
97. Harpel PC, Sullivan R and Chang T-S. Binding and activation of plasminogen on immobilized immunoglobulin G. J Biol Chem 1989; 264: 616-24.
98. Boivin D, Provençal M, Gendron S, et al. Purification and characterization of a stimulator of plasmin from the antiangiogenic agent Neovastat: identification as immunoglobulin kappa light chain. Arch Biochem Biophys 2004; 431:197-206.
99. Stehouver CD, Lambert J, Donker AJ, van Hinsbergh VW. Endothelial dysfunction and pathogenesis of diabetic angiopathy. Cardiovasc Res 1997; 34: 55-68.
100. Meigs JB, Mittleman MA, Nathan DM, et al. Hyperinsulinemia, hyperglycemia, and impaired hemostasis. JAMA 2000, 283: 221-8.
101. Simpson AJ, Booth NA, Moore NR, Lewis SJ, Gray RS. Circulating tissue-type plasminogen activator and plasminogen activator inhibitor type 1 in proliferative diabetic retinopathy: a pilot study. Acta Diabetol 1999; 36: 155-8.
102. Schalkwijk CG, Poland DCW, van Dijk W, et al. Plasma concentration of C-reactive protein is increased in Type 1 diabetic patients without clinical macroangiopathy and correlates with markers of endothelial disfunction: evidence for chronic inflammation. Diabetologia 1999; 42: 351-7.
103. Bosnyak Z, Forrest KY-Z, Maser RE, Becker D and Orchard TJ. Do plasminogen activator inhibitor (PAI-1) or tissue plasminogen activator PAI-1 complexes predict complications in Type 1 diabetes: the Pittsburgh Epidemiology of Diabetes Complications Study. Diab Med 2003; 20: 147-51.
104. Carr ME. Diabetes mellitus: a hypercoagulable state. J Diab Complications 2001; 15: 44-54.
105. Jaffa AA, Durazo-Arvizu R, Zheng D, et al. Plasma prekallikrein: a risk marker for hypertension and nephropathy in type 1 diabetes. Diabetes 2003; 52: 1215-21.
106. Finotti P, Piccoli A, Carraro P. Alterations of plasma proteinase-antiproteinase system in type 1 diabetic patients. Influence of sex and relationship with metabolic control. Diabetes Res Clin Pract 1992; 18: 35-42.
107. Sandler M, Stewart RI, Gemperly BM, Hanekom C, Kühn H. Serum alpha-1-protease inhibitor activity and pulmonary function in young insulin-dependent diabetic subjects. Respiration 1987; 52: 281-9.
108. 1-antitrypsin gene. Arterioscler Thromb Vasc Biol 2003; 23: 644-9.
109. Semenkovich CF, Heinecke JW. The mistery of diabetes and atherosclerosis: time for a new plot. Diabetes 1997; 46: 327-34.
110. Srinivasan S, Bolick DT, Hatley ME, et al. Glucose regulates interleukin-8 production in aortic endothelial cells through activation of the p38 mitogen-activated protein kinase pathway in diabetes. J Biol Chem 2004; 279: 31930-6.
111. Yamagishi S, Fujimori H, Yonekura H, Yamamoto Y, Yamamoto H. Advanced glycation endproducts inhibit prostaclycin production and induce plasminogen activator inhibitor-1 in microvascular endothelial cells. Diabetologia 1998; 41: 1435-41.
112. Yamagishi S, Yonekura H, Yamamoto Y, et al. Advanced glycation end products-driven angiogenesis in vitro. J Biol Chem 1997; 272: 8723-30.
113. Finotti P, Pagetta A, Ashton T. The oxidative mechanism of heparin interferes with radical production by glucose and reduces the degree of glycooxidative modifications on human serum albumin. Eur J Biochem 2001; 268: 2193-200.
114. Schiekofer S, Balletshofer B, Andrassy M, Bierhaus A, Nawroth PP. Endothelial dysfunction in diabetes mellitus. Semin Thromb Hemost 2000; 26: 503-11.
115. Goldberg IJ. Why does diabetes increase atherosclerosis? I don't know! J Clin Invest 2004; 114: 613-5.
116. Stehouwer CD, Fisher HR, van Kuijk AW, Polak BC, Donker AJ. Endothelial dysfunction precedes development of micro-albuminuria in IDDM. Diabetes 1995; 44: 561-4.
117. Romano M, Pomilio M, Vigneri S, et al. Endothelial perturbation in children and adolescents with type 1 diabetes. Diabetes Care 2001; 24: 1674-8.
118. Microalbuminuria Collaborative Study Group, UK. Intensive therapy and progression to clinical albuminuria in patients with insulin dependent diabetes mellitus and microalbuminuria. Br Med J 1995; 311: 973-7.
119. Rogus JJ, Warram JH, Krowleski AS. Genetic studies of late diabetic complications. The overlooked importance of diabetes duration before complication onset Diabetes 2002; 51: 1655-62.
120. Marre M. Genetics and the prediction of complications in type 1 diabetes. Diabetes Care 1999; S2: B53-8.
121. Rippin JD, Patel A, Bain SC. Genetics of diabetic nephropathy. Best Pract Res Clin Endocrinol Metab 2001; 15: 345-58.
122. Fomoni A, Striker LJ, Zheng F, Striker GE. Reversibility of glucose-induced changes in mesangial cell extracellular matrix depends on the genetic background. Diabetes 2002; 51: 499-505.
123. Toivonen A, Kulmala P, Savola K, Åkerblom HK, Knip M and the Childhood Diabetes in Finland Study Group. Soluble adhesion molecules in preclinical Type 1 diabetes. Pediatr Res 2001; 49: 24-9.
124. Murciano J-C, Muro S, Koniaris L, et al. ICAM-directed vascular immunotargeting of antithrombotic agents to the endothelial luminal surface. Blood 2003; 101:3977-84.
125. Hanninen A, Jalkanen S, Salmi M, Toikkanen S, Nikolakaros G, Simell O. Macrophages, T cell receptor usage, and endothelial cell activation in the pancreas at the onset of insulin-dependent diabetes mellitus. J Clin Invest 1992; 90: 1901-10.
126. Yagi N, Yokono K, Amano K, et al. Expression of intercellular adhesion molecule 1 on pancreatic beta-cells accelerates beta-cell destruction by cytotoxic T-cells in murine autoimmune diabetes. Diabetes 1995; 44: 744-52.
127. Manderson JG, Mullan B, Patterson CC, Hadden DR, Traub AI, Mc Cance DR. Cardiovascular and metabolic abnormalities in the offspring of diabetic pregnancy. Diabetologia 2002; 45: 991-6.
128. Burkart V, Liu H, Bellmann D, et al. Natural resistance of human beta cells toward nitric oxide is mediated by heat shock protein 70. J Biol Chem 2000; 275: 19521-8.
129. Lei H, Romeo G, Kazlauskas A. Heat shock protein 90 α-dependent translocation of annexin II to the surface of endothelial cells modulates plasmin activity in the diabetic rat aorta. Circ Res 2004; 94: 902-9.
130. Qin H-Y, Mahon JL, Atkinson MA, Chaturvedi P, Lee-Chan E, Singh B. Type 1 diabetes alters anti-hsp90 autoantibody isotype. J Autoimmun 2003; 20: 237-45.
131. Pagetta A, Folda A, Brunati AM, Finotti P. Identification and purification from the plasma of Type 1 diabetic patients of a proteolytically active Grp94. Diabetologia 2003; 46: 996-1006.
132. Mantova S, Raevb D. Additive effect of diabetes and systemic hypertension on the immune mechanisms of atherosclerosis. Int J Cardiol 1996; 56: 145-8.
133. Bonifacio E, Scirpoli M, Kredel K, Füchtenbush M and Ziegler A-G. Early autoantibody responses in prediabetes are IgG1 dominated and suggest antigen-specific regulation. J Immunol 1999; 163: 525-32.
134. Schmidt KD, Valeri C, Leslie RDG. Autoantibodies in Type 1 diabetes. Clin Chim Acta 2005; 354: 35-40.
135. Ciarla MV, Bocciarelli A, Di Gregorio S, et al. Autoantibodies and endothelial dysfunction in well-controlled, uncomplicated insulin-dependent diabetes mellitus patients. Atherosclerosis 2001; 158: 241-6.
136. 1-antitrypsin in plasma of Type 1 diabetic subjects. Biochem Biophys Res Commun 2004; 315: 297-305.
137. Galtier-Dereure F, Biron C, Vies M, Bourgeois V, Schved J-F and Bringer J. Vascular complications of diabetes mellitus: what role for phospholipid-binding antibodies? 1998; Lupus 7: 469-74.
138. Izadyar L, Friboulet A, Remy MH, Roseto A and Thomas D. Monoclonal anti-idiotypic antibodies as functional internal images of enzyme active sites: production of a catalytic antibody with a cholinesterase activity. Proc Natl Acad Sci USA 1993; 90: 8876-80.
139. Paul S, Tramontano A, Gololobov G, et al. Phosphonate ester probes for proteolytic antibodies. J Biol Chem 2001; 276: 28314-20.
140. Kolesnikov AV, Kozyr AV, Alexandrova ES, et al. Enzyme mimicry by the antiidiotypic antibody approach. Proc Natl Acad Sci USA 2000; 97; 13526-31.
141. Lefevre S, Debat H, Thomas D, Friboulet A, Avalle B. A suicide-substrate mechanism for hydrolysis of β -lactams by an antiidiotypic catalytic antibody. FEBS Lett 2001; 489: 25-8.
142. Planque S, Taguchi H, Burr G, et al. Broadly distributed chemical reactivity of natural antibodies expressed in coordination with specific antigen binding activity. J Biol Chem 2003; 278: 20436-43.
143. Tawfik DS, Chap R, Green BS, Sela M and Eshhar Z. Unexpectedly high occurrence of catalytic antibodies in MRL/lpr and SJL mice immunized with a transition-state analog: is there a linkage to autoimmunity? Proc Natl Acad Sci USA 1995; 92: 2145-9.